Posters

Severe ocular pemphigoid treated with a combination therapy of intravenous immunoglobulin and rituximab

Poster Details

First Author: A. Calle SPAIN

Co Author(s):    B. Sarmiento Torres   J. Torres Pena   C. Navarro Perea   L. Hernandez Pereira   A. Ortueta Olartecoechea   A. De Pablo Cabrera     

Abstract Details

Purpose:

To report a severe ocular pemphigoid case treated with a combination therapy of intravenous immunoglobulin (IVIg) and rituximab

Setting:

12 de Octubre Universitary Hospital, Ophthalmology Deparment, Complutense University, Madrid, Spain

Methods:

A 80 years-old woman with diagnosis of severe ocular pemphigoid with no response to high-dose corticosteroids, cyclophosphamide, cyclosporin, azathioprine, dapsone, and mycophenolate mofetil. The diagnosis was based on histopathology and confirmed by direct immunofluorescence. In this case we decided to use combination therapy with intravenous immunoglobulin 660mg/kg (Octagamocta®) and rituximab 375 mg/m2 (Mabthera®) 3 doses each, monthly, during 3 months.

Results:

After 3 months of treatment with IVIg and rituximab, there was no progression in conjunctival cicatrization meaning an stabilization of the severe ocular compromise.

Conclusions:

In cases of severe ocular pemphigoid with not response to conventional immunosuppressive therapy, the combination therapy with IVIg and rituximab could be used to stop the progression of the severe ocular compromise

Financial Disclosure:

NONE